AbCellera Biologics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Xencor 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

MacroGenics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Zymeworks 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Janux Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Vaxcyte 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Travere Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

A focused 2026 clinical landscape deep dive into NCT07680829, evaluating Icosapent Ethyl in Hypertriglyceridemia: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07701993, evaluating Efimosfermin alfa in MASH Cirrhosis: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07596329, evaluating Furosemide in Cardiorenal Syndrome: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07635914, evaluating Aprocitentan in Resistant Hypertension: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.

A focused 2026 clinical landscape deep dive into NCT07693777, evaluating DR-10624 in Hypertriglyceridemia: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.